Partnerships, Licensing, Investments and M&A Deals and Trends for April 2019 in Pharmaceuticals

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for April 2019 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in April 2019. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the six months.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Pharmaceuticals & Healthcare, Global, Deal ...

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Pharmaceuticals & Healthcare, Global, Deal Summary 10

2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, April 2019 10

2.2 Pharmaceuticals & Healthcare, Global, Major Deals, April 2019 12

2.2.1 Novartis Acquires IFM Tre 12

2.2.2 Catalent Acquires Paragon Bioservices for USD1.2 Billion 12

2.2.3 Cytovant Sciences Enters into Licensing Agreement with Medigene 13

2.2.4 Alnylam Pharma and Regeneron Pharma to Enter into Partnership 13

2.2.5 Everest Medicines II Enters into Licensing Agreement with Immunomedics 14

2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, April 2019 16

2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, April 2019 17

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 18

3.1 Pharmaceuticals & Healthcare, Global, M&A, April 2019 18

3.1.1 Top M&A Deals in April 2019 19

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, November 2018 – April 2019 20

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, April 2019 21

3.2.1 Top Equity Offering Deals in April 2019 22

3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, November 2018 – April 2019 23

3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, April 2019 24

3.3.1 Top PE/VC Deals in April 2019 25

3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, April 2019 26

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, April 2019 27

3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, June 2016–April 2019 29

3.3.7 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, June 2016–April 2019 30

3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, April 2019 31

3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, November 2018 – April 2019 32

3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), April 2019 33

3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, April 2019 34

3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), November 2018 – April 2019 35

3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, November 2018 – April 2019 37

3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), November 2018 – April 2019 38

3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), November 2018 – April 2019 39

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, April 2019 40

4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, April 2019 40

4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), April 2019 41

4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), November 2018 – April 2019 42

4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), November 2018 – April 2019 44

4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), November 2018 – April 2019 45

4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), November 2018 – April 2019 47

4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, April 2019 48

4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, April 2019 49

4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, April 2019 49

5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 50

5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, April 2019 50

5.1.1 Oncology – Deals of the Month 51

5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, April 2019 53

5.2.1 Central Nervous System – Deals of the Month 54

5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, April 2019 56

5.3.1 Infectious Diseases – Deals of the Month 57

5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, April 2019 58

5.4.1 Cardiovascular – Deals of the Month 59

5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, April 2019 60

5.5.1 Immunology – Deal of the Month 61

5.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, April 2019 63

5.6.1 Gastrointestinal – Deals of the Month 64

5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, April 2019 66

5.7.1 Metabolic Disorders – Deals of the Month 67

6 Deal Summary by Geography 68

6.1 Pharmaceuticals & Healthcare, North America Deals, April 2019 68

6.1.1 North America – Deals of the Month 69

6.2 Pharmaceuticals & Healthcare, Europe, Deals, April 2019 72

6.2.1 Europe – Deals of the Month 73

6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, April 2019 75

6.3.1 Asia-Pacific – Deals of the Month 76

6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, April 2019 78

6.4.1 Rest of the World – Deals of the Month 79

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 81

7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, November 2018 – April 2019 81

7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, November 2018 – April 2019 82

8 Further Information 83

8.1 Methodology 83

8.2 About GlobalData 84

8.3 Contact Us 84

8.4 Disclosure information 84

8.5 Disclaimer 85

List of Tables

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 ...

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 11

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, April 2019 12

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), April 2019 17

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 19

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, April 2019 19

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2018 – April 2019 20

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 22

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, April 2019 22

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 23

Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 25

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, April 2019 25

Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, November 2018 – April 2019 26

Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), April 2019 28

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 29

Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, November 2018 – April 2019 30

Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 31

Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 32

Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2018 – April 2019 33

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), April 2019 34

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2018 – April 2019 36

Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2018 – April 2019 38

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), November 2018 – April 2019 39

Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 40

Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), November 2018 – April 2019 41

Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 43

Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), April 2019 44

Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2018 – April 2019 46

Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), April 2019 48

Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, April 2019 48

Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, April 2019 49

Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, April 2019 49

Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 51

Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 54

Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 57

Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 59

Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 61

Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 64

Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 67

Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 69

Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 73

Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 76

Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 79

Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 81

Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 82

List of Figures

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 10

Figure ...

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 10

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), April 2019 16

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), April 2019 17

Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 18

Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2018 – April 2019 20

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 21

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 23

Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 24

Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2018 – April 2019 26

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), April 2019 27

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), April 2019 28

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 29

Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 31

Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 32

Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2018 – April 2019 33

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2018 – April 2019 35

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2018 – April 2019 37

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2018 – April 2019 38

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), November 2018 – April 2019 39

Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 40

Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2018 – April 2019 41

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 42

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2018 – April 2019 44

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, November 2018 – April 2019 45

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), November 2018 – April 2019 46

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), April 2019 47

Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 50

Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 53

Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 56

Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 58

Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 60

Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 63

Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 66

Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 68

Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 72

Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 75

Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 78

Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 81

Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), November 2018 – April 2019 82

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports

GlobalData provide us with all needed up-to-date market information on any compound or any pharma company in the world.

  International Investment Firm